Canada Markets open in 5 hrs 15 mins

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
130.30+2.65 (+2.08%)
At close: 04:00PM EDT
130.34 +0.04 (+0.03%)
After hours: 07:38PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close127.65
Bid0.00 x 900
Ask0.00 x 1000
Day's Range128.00 - 133.41
52 Week Range117.08 - 374.58
Avg. Volume932,901
Market Cap31.6B
Beta (5Y Monthly)-0.08
PE Ratio (TTM)4.13
EPS (TTM)31.54
Earnings DateNov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJun 02, 2022
1y Target Est244.89
  • Zacks

    Pfizer (PFE) Seeks FDA Approval for Omicron Booster in Kids

    Pfizer (PFE) and partner BioNTech seek authorization from the FDA for using their bivalent COVID-19 booster vaccine in kids. The vaccine is already authorized for use in adolescents and adults.

  • Reuters

    UPDATE 1-Pfizer/BioNTech seek FDA nod for new COVID boosters for children

    Pfizer Inc and its German partner BioNTech on Monday sought the U.S. Food and Drug Administration's authorization for an Omicron-tailored COVID-19 vaccine booster for children aged 5 through 11 years. The application comes just days after Moderna also applied for FDA authorization of its own Omicron-targeting shot in adolescents aged 12 to 17 years and children aged six to 11. The applications represent a step towards getting children vaccinated by a so-called bivalent vaccine, which targets both the original strain of the virus and the circulating BA.4 and BA.5 subvariants of Omicron.

  • Business Wire

    Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age

    NEW YORK & MAINZ, Germany, September 26, 2022--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) of a 10-µg booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children ages 5 through 11 years of age. The request for Emergency Use Authorization of the Omicron BA.4/BA.5-adapted bivalent vaccine in this age group is sup